Intervention Review

You have free access to this content

Treatment of Kaposi sarcoma in children with HIV-1 infection

  1. Andrew Anglemyer1,*,
  2. Anurag K Agrawal2,
  3. George W Rutherford1

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 27 JAN 2014

Assessed as up-to-date: 23 JAN 2014

DOI: 10.1002/14651858.CD009826.pub2


How to Cite

Anglemyer A, Agrawal AK, Rutherford GW. Treatment of Kaposi sarcoma in children with HIV-1 infection. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD009826. DOI: 10.1002/14651858.CD009826.pub2.

Author Information

  1. 1

    University of California, San Francisco, Global Health Sciences, San Francisco, California, USA

  2. 2

    Children's Hospital and Research Center Oakland, Oncology, Oakland, California, USA

*Andrew Anglemyer, Global Health Sciences, University of California, San Francisco, San Francisco, California, 94105, USA. andrew.anglemyer@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 27 JAN 2014

SEARCH

[Figure 1]
Figure 1. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. Study Flow Diagram
[Figure 3]
Figure 3.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Chemotherapy + ART vs ART, outcome: 1.1 Complete Response to Treatment.
[Figure 5]
Figure 5. Forest plot of comparison: 4 Chemotherapy + ART vs ART, outcome: 4.5 Mortality
[Analysis 1.1]
Analysis 1.1. Comparison 1 Chemotherapy + ART vs ART, Outcome 1 Complete Response to Tx.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Chemotherapy + ART vs ART, Outcome 2 Complete/Partial Response to Tx.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Chemotherapy + ART vs ART, Outcome 3 Complete Among Known Outcome.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Chemotherapy + ART vs ART, Outcome 4 Complete/Partial Among Known Outcome.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Chemotherapy + ART vs ART, Outcome 5 Mortality.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Chemotherapy + ART vs ART, Outcome 6 Mean CD4% Increase During Chemo.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Vincristine + ART vs Bleomycin + vincristine + ART, Outcome 1 Complete: Vincristine+ART vs Bleomycin+vincristine+ART.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Vincristine + ART vs Bleomycin + vincristine + ART, Outcome 2 Complete/Partial: Vincristine+ART vs Bleomycin+vincristine+ART.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Vincristine + ART vs Bleomycin + vincristine + ART, Outcome 3 Complete: Vincristine+ART vs Bleomycin+vincristine+ART.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Vincristine + ART vs Bleomycin + vincristine + ART, Outcome 4 Complete/Partial: Vincristine+ART vs Bleomycin+vincristine+ART.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Combination Chemotherapy + ART vs Single Agent Chemotherapy + ART, Outcome 1 Mortality.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Chemotherapy + ART vs Chemotherapy Alone, Outcome 1 Complete Response to Tx.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Chemotherapy + ART vs Chemotherapy Alone, Outcome 2 Complete/Partial Response to Tx.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Chemotherapy + ART vs Chemotherapy Alone, Outcome 3 Complete Among Known Outcome.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Chemotherapy + ART vs Chemotherapy Alone, Outcome 4 Complete/Partial Among Known Outcome.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Chemotherapy + ART vs Chemotherapy Alone, Outcome 5 Mortality.
[Analysis 5.1]
Analysis 5.1. Comparison 5 ART vs Vincristine or Bleomycin, Outcome 1 Complete: ART vs Bleomycin or vincristine.
[Analysis 5.2]
Analysis 5.2. Comparison 5 ART vs Vincristine or Bleomycin, Outcome 2 Complete/Partial: ART vs Bleomycin or vincristine.